Protagenic Therapeutics, Inc. (PTIX) Stock
Protagenic Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to the research and development of novel treatments designed to address neuropsychiatric and mood conditions exacerbated by stress.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
About Protagenic Therapeutics, Inc.
Protagenic Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to the research and development of novel treatments designed to address neuropsychiatric and mood conditions exacerbated by stress. Foremost among its investigational products is PT00114, a laboratory-synthesized version of the teneurin carboxy-terminal associated peptide. This compound functions by emulating an innate brain signaling peptide, known for its ability to temper exaggerated stress reactions. The company's headquarters are located in New York, New York.
Protagenic Therapeutics, Inc. is headquartered in US.
Protagenic Therapeutics, Inc. (PTIX) stock trades at $0.26 with a market capitalization of $470654. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.08, reflecting a net loss over the last twelve months, a negative price-to-book of -0.21, reflecting negative shareholders' equity, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.14 and $6.20, and currently trades 95.8% below its 52-week high.
On profitability, Protagenic Therapeutics, Inc. generates a return on equity (ROE) of 184.88% (not meaningful, as shareholders' equity is negative), return on capital employed of 124.29%.
Official website: www.protagenic.com
Protagenic Therapeutics, Inc. by the numbers, 2016–2025
Between 2016 and 2025 Protagenic Therapeutics, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-5.0M.
On a trailing twelve-month basis to Dec '25, revenue is $0 and net profit $-5.0M.
Borrowings stand at $3.0M, cash on hand is $2.2M, cash from operations was $-4.0M in the latest year, positive in 0 of the last 10.
Return on equity has averaged -116.4% over five years, and was 250.0% in the most recent year.
The share price itself has compounded at —% a year over five years, -79.3% over three, -93.0% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
Protagenic Therapeutics, Inc. (PTIX) — frequently asked questions
What is Protagenic Therapeutics, Inc. (PTIX) stock price today?
Protagenic Therapeutics, Inc. (PTIX) is currently trading at $0.26, up 18.18% today.
What is PTIX P/E ratio?
Protagenic Therapeutics, Inc.'s P/E ratio is -0.08. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is PTIX return on equity (ROE)?
Protagenic Therapeutics, Inc.'s return on equity (ROE) is 184.88%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.
What is Protagenic Therapeutics, Inc.'s market cap?
Protagenic Therapeutics, Inc. has a market capitalization of $470654.
Does PTIX pay a dividend?
Protagenic Therapeutics, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does PTIX carry?
Protagenic Therapeutics, Inc. has a debt-to-equity ratio of -1.32. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is PTIX's profit margin?
Protagenic Therapeutics, Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.
What sector is PTIX in?
Protagenic Therapeutics, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is PTIX listed on?
Protagenic Therapeutics, Inc. trades on NASDAQ under the ticker PTIX.
What is PTIX's 52-week range?
Over the last year Protagenic Therapeutics, Inc. has traded between $0.14 and $6.20.
Related Healthcare Stocks
Popular Stocks
Screens PTIX currently matches
On the figures above, Protagenic Therapeutics, Inc. passes the filters for 4 of our ready-made screens, among them Day Gainers Stocks, Penny Stocks, Stocks Under $1. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.